Dataset Information

Proteomic response of diffuse midline glioma to HDAC inhibition reveals adjuvant anti-EBP50 therapy as novel therapeutic concept.

ABSTRACT: Diffuse midline glioma (DMG) is an aggressive pediatric tumor localized in the brainstem. The median survival after diagnosis is less than one year. Surgical resection is not possible due to the critical localization of the tumor and radiation therapy alone or in combination with chemotherapy show only minimal benefit. In 80% of cases, DIPGs are harbor genetic abnormalities such as a K27M mutation in histone H3, suggesting drugs targeting epigenetic anomalies might be efficient. Indeed, Grasso et al. (Nature Medicine, 2015) have shown that the histone deacetylase inhibitor panobinostat (PS) affects glioma cell growth in vitro and in vivo. PS is currently undergoing phase 1 clinical trials. To better understand the mechanism of action of PS on tumor cells, we performed a proteomic analysis by comparing DMG cells treated with panobinostat to control cells. We identified 2 proteins in PS-treated cells: EBP50 (or NHERF-1) and IRSp53 (or BAIAP2). EBP50 protein is implicated in invasion (Kislin et al. Neoplasia, 2009) but it can also act like a tumor suppressor on glioblastoma (Molina et al. Cancer Research, 2010). There is a dual role of the protein which depends on its localization in the cell: when localized at the cell membrane, EBP50 acts as a tumor suppressor, but has oncogenic properties when present in the cytoplasm or nucleus. Using electron microscopy combined with immunofluorescence, we could validate expression of EBP50 in all cellular compartments. IRSp53 is implicated in proliferation of tumor cells (Liu P.S. Oncogene, 2010) and may have an important role during migration and invasion (Funato et al., Cancer Research 2004). To elucidate the role of the two proteins in DIPG, we investigated effects of gene knockdown by siRNA and stable overexpression using lentiviruses. For each protein, we found a significant diminution of proliferation, migration and invasion and an increase in apoptosis cells were transfected with siRNAs. In contrast, overexpression of EBP50 did not have any effect on cells. Our results suggest that the two proteins induced by PS treatment are implicated in tumor progression and might constitute novel additional therapeutic targets, especially as adjuvant treatment together with PS.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Dupuy Jean-William

LAB HEAD: Martin Hagedorn

PROVIDER: PXD009666 | Pride | 2021-06-10

REPOSITORIES: Pride

ACCESS DATA

Publications

HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.

Capdevielle Caroline C Desplat Angélique A Charpentier Justine J Sagliocco Francis F Thiebaud Pierre P Thézé Nadine N Fédou Sandrine S Hooks Katarzyna B KB Silvestri Romano R Guyonnet-Duperat Veronique V Petrel Melina M Raymond Anne-Aurélie AA Dupuy Jean-William JW Grosset Christophe F CF Hagedorn Martin M

Neuro-oncology 20200401 4

<h4>Background</h4>Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors such as panobinostat (PS) is therefore a novel therapeutic option currently evaluated in clinical trials.<h4>Methods</h4>BH3 profiling revealed engagement in an irreversibl ...[more]

PMID: 31711240

Similar Datasets

Project description:Comparison of polysomal profiles of murine adult olig2 cortical progenitors, murine tumor olig2 cells derived from hPDGF-B-driven glioblastomas, and murine olig2 proliferative recruited glioma cells contributing to the tumor mass but not derived from the cell of origin An unbiased way to define a cell population lies in identification of its gene expression signature and subsequent comparison to gene expression signatures of known normal or cancer cells to define its position on the axis of tumorigenesis. To quantify similarities and differences in the expression profiles of recruited cells and tumor cells using microarray analysis, we used the bacTRAP technology that allows immunoprecipitation of polysomes from specific cell types in vivo (Heiman et al 2008, Doyle et al 2008). We compared polysomal expression profiles of hPDGFb-driven Ntv-a Ink4a/Arf+/- olig2 mouse glioma cells representing a histologically defined glioma population, recruited olig2 cells derived from Ink4a/Arf+/- olig2 RP-eGFP mice transplanted with non-fluorescent glioma cells, and normal adult cortical olig2 mouse progenitors, using Affymetrix 430 mouse 2.0 chips and Genespring GX10 software (Doyle et al 2008, Heiman et al 2008). Translational profiles of recruited olig2 cells and glioma olig2 cells were similar to each other and clearly distinct from the normal olig2 progenitors, majority of the differences accounted for by the “statistically significantly changed” set of mRNAs (ANOVA, p<0.05), and sample clustering reduced upon removal of the ANOVA-tested mRNA set. Unsupervised hierarchical mRNA clustering likewise indicated that recruited olig2 cells clustered more closely to glioma olig2 cells. The caveat is that olig2 expression in the adult normal brain of bacTRAP olig2 RP-eGFP mice labels both progenitors and mature oligodendrocytes, while recruited and tumor olig2 cells are almost entirely progenitors; therefore, some of the differences seen in the comparative analysis of normal, tumor and recruited olig2 cells may in part result from the shift in relative abundance of different progenitor and mature olig2 cell populations. Normal olig2 progenitors were collected from three replicates of pooled cortices of three olig2 RP-eGFP bacTRAP reporter mice. Mouse gliomas induced by injection of a non-fluorescent RCAS-hPDGFb (Shih et al 2004) or by transplantation of muring glioma cells derived from Ntv-a gliomas induced by the non-fluorescent RCAS-hPDGFb were collected from Ntv-a olig2 RP-eGFP bacTRAP reporter mice and immunoprecipitated; each tumor was processed as a separate sample. Briefly, mouse tissues were collected into ice-cold cyclohexamide-containing buffer, homogenized, cells were lysed in NP-40 and DHPC-containing buffer, centrifuged at 20,000g for 15 min, supernatant incubated with anti-eGFP-conjugated protein G beads 30 min at 4C, washed and RNA collected using Trizol reagent as per manufacturer’s instructions (Doyle et al., 2008; Heiman et al., 2008). RNA was purified, concentrated using Qiagen RNeasy kit, its quality confirmed by Agilent Bioanalyzer, 15ng per sample amplified using Affymetrix Two-Cycle Amplification kit and hybridized to Affymetrix 430 mouse 2.0 chips as described in Doyle et al., 2008; Heiman et al., 2008. Data was analyzed using Genespring GX10 software, as described in the text and in Doyle et al., 2008; Heiman et al., 2008. Briefly, samples were normalized using GCRMA, filtered to remove probe sets with low intensity, and analyzed using ANOVA (p<0.05) with SNK post-hoc and Benjamini and Hochberg FDR multiple testing correction. Probe quality, Pearson’s correlation, hierarchical clustering, heatmaps, gene profile plots were generated using Genespring GX10 software. Pathway analysis was performed using Ingenuity as per manufacturer’s instructions.

Dataset Information

Proteomic response of diffuse midline glioma to HDAC inhibition reveals adjuvant anti-EBP50 therapy as novel therapeutic concept.

Publications

HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure